Solving the solubility setback

Poor solubility can be a real issue during drug development, as it can lead to low bioavailability, which causes suboptimal drug delivery, and often risks the drug being withdrawn from development.

The HTS approach shortens the time necessary to identify which excipients can adequately solubilise a compound, as well as which excipients a compound can remain stable in.

 

Yet the complex and vital process of solubility testing to identify the best excipients is currently based on a trial-and-error methodology. This is time-consuming, expensive and uses lots of API, which has fuelled the development of a new method that can optimise the selection of excipients.

As well as reducing time and cost, Recipharm’s high-throughput screening (HTS) method is a robust and automatic approach that requires minimal amounts of the compound in order to produce conclusive information. Unlike current excipient testing methods, which test every excipient manually, this methodology involves multiple tests being undertaken concurrently.

Dr. Amjad Alhalaweh, a research scientist at Recipharm describes the HTS approach in Contract Pharma. Read the full article here.